<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066767</url>
  </required_header>
  <id_info>
    <org_study_id>02041</org_study_id>
    <nct_id>NCT01066767</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg
      Tablets of Dr.Reddy's Laboratories Limited, and Allegra® 180 mg Tablets aventis Administered
      as

      1 x 180 mg Tablet in Healthy Subjects under Fed Conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of fexofenadine
      hydrochloride 180 mg tablets (test) versus Allegra® (reference) administered as 1 x 180 mg
      tablet under fasting conditions. Single oral dose (1 x 180 mg) in each period with a washout
      of at least 7 days between doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study of Dr. Reddys, Fexofenadine Hydrochloride 180 mg tablets</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fexofenadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allegra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Fexofenadine Hydrochloride 180 mg Tablets</description>
    <arm_group_label>Fexofenadine</arm_group_label>
    <arm_group_label>Allegra</arm_group_label>
    <other_name>Allegra 180 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects enrolled in this study will be members of the community at large. The recruitment
        advertisements may be done using different media (e.g. radio, newspaper, Anapharm Inc.

        Web site, Anapharm Inc. volunteers' data base). Subjects must meet all of the following
        criteria in order to be included in the study:

          -  Subjects will be females and/or males, smokers and non-smokers, 18 years of age and
             older.

          -  Female subjects will be post-menopausal or surgically sterilized.

               -  Post-menopausal status is defined as absence of menses for the past 12 months or
                  hysterectomy with bilateral oophorectomy at least 6 months ago.

               -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal
                  ligation at least 6 months ago.

        Exclusion Criteria:

          -  Subjects to whom any of the following applies will be excluded from the study:

               -  Clinically significant illnesses within 4 weeks of the administration of study
                  medication.

               -  Clinically significant surgery within 4 weeks prior to the administration of the
                  study medication.

               -  Any clinically significant abnormality found during medical screening.

               -  Any reason which, in the opinion of the medical sub investigator, would prevent
                  the subject from participating in the study.

               -  Abnormal laboratory tests judged clinically significant.

               -  Positive urine drug screen at screening.

               -  Positive testing for hepatitis B, hepatitis C or HN at screening.

               -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic
                  blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower
                  than 50 or over 90; or heart rate less than 50 bpm or over 100 bpm) at screening.

               -  Subjects with BMl ≥ 30.0.

               -  History of significant alcohol abuse within six months of the screening visit or
                  any indication of the regular use of more than two units of alcohol per day (1
                  Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

               -  History of drug abuse or use of illegal drugs: use of soft drugs (such as
                  marijuana) within 3 months of the screening visit or hard drugs (such as cocaine,
                  phencyclidine (PCP) and crack) within 1 year of the screening visit.

               -  Any food allergy, intolerance, restriction or special diet that, in the opinion
                  of the medical Sub investigator, contraindicates the subject's participation in
                  this study.

               -  History of allergic reactions to fexofenadine hydrochloride or its ingredients.

               -  History of allergic reactions to heparin.

               -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
                  inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids,
                  rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine,
                  diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil,
                  quinidine), use of an investigational drug or participation in an investigational
                  study within 30 days prior to administration of the study medication.

               -  Use of prescription medication within 14 days prior to administration of study
                  medication or over-the-counter products (including natural products, vitamins,
                  garlic as supplement)within 7 days prior to administration of study medication,
                  except for topical products without systemic absorption.

               -  Subjects who have a depot injection or an implant of any drug 3 months prior to
                  administration of study medication.

               -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior
                  to administration of the study medication as follows:

               -  less than 300 mL of whole blood within 30 days or

               -  300 mL to 500 mL of whole blood within 45 days or

               -  more than 500 mL of whole blood within 56 days.

               -  Smoking more than 25 cigarettes per day.

        Additional exclusion criteria for females only:

          -  Breast-feeding subjects.

          -  Positive urine pregnancy test at screening (performed on all females).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.,</name>
      <address>
        <city>Sainte-Foy Quebec</city>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

